Cargando…

An alternative approach for estimating the number needed to treat for survival endpoints

To investigate the issues of the NNT based on the absolute risk reduction (ARR), namely NNT(ARR); and to propose an alternative definition and an estimation procedure based on the restricted mean survival time (RMST), namely NNT(RMST), for RCTs. Three recent clinical trials with survival endpoints,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhao, Yin, Guosheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799908/ https://www.ncbi.nlm.nih.gov/pubmed/31626655 http://dx.doi.org/10.1371/journal.pone.0223301

Ejemplares similares

Reduction in number to treat versus number needed to treat
por: Zhang, Chenyang, et al.
Publicado: (2021)

The empirical estimate of the survival and variance using a weighted composite endpoint
por: Nabipoor, Majid, et al.
Publicado: (2023)

Rivaroxaban: An Evaluation of its Cardiovascular Benefit–Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons
por: Ageno, Walter
Publicado: (2015)

The number needed to treat adjusted for explanatory variables in regression and survival analysis: Theory and application
por: Vancak, Valentin, et al.
Publicado: (2022)

On the number of trials needed to distinguish similar alternatives
por: Chierichetti, Flavio, et al.
Publicado: (2022)

Is more involvement needed in the clinical trial design & endpoints?
por: Vroom, Elizabeth
Publicado: (2012)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Analysis of Group Randomized Trials with Multiple Binary Endpoints and Small Number of Groups
por: Lee, Ji-Hyun, et al.
Publicado: (2009)

Number needed to treat (NNT) in clinical literature: an appraisal
por: Mendes, Diogo, et al.
Publicado: (2017)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

The cytotoxicity of polycationic iron oxide nanoparticles: Common endpoint assays and alternative approaches for improved understanding of cellular response mechanism
por: Hoskins, Clare, et al.
Publicado: (2012)

The Holy grail, genes and Number Needed to Treat
por: Herbert, Mel
Publicado: (2007)

Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies
por: Yin, Guosheng, et al.
Publicado: (2020)

When do we need clinical endpoint adjudication in clinical trials?
por: Held, Claes
Publicado: (2019)

Association of response endpoints with survival outcomes in multiple myeloma
por: Lonial, S, et al.
Publicado: (2014)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
por: Ohlmann, Carsten-Henning
Publicado: (2012)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival
por: Birgisson, Helgi, et al.
Publicado: (2011)

The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research
por: Roy, Neeta S., et al.
Publicado: (2017)

Probabilistic Estimation of Identity by Descent Segment Endpoints and Detection of Recent Selection
por: Browning, Sharon R., et al.
Publicado: (2020)

Automatic Identification of the Repolarization Endpoint by Computing the Dominant T-wave on a Reduced Number of Leads
por: Giuliani, C., et al.
Publicado: (2016)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Pooling data for Number Needed to Treat: no problems for apples
por: Moore, R Andrew, et al.
Publicado: (2002)

Meta-analysis, Simpson's paradox, and the number needed to treat
por: Altman, Douglas G, et al.
Publicado: (2002)

Number Needed to Treat in Multiple Sclerosis Clinical Trials
por: Okwuokenye, Macaulay, et al.
Publicado: (2017)

COVID-19 vaccines: effectiveness and number needed to treat
por: Correia, Luis C L, et al.
Publicado: (2021)

Commentary: Coronary revascularization therapies and number needed to treat
por: Dimagli, Arnaldo, et al.
Publicado: (2022)

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges
por: Angel, Juana, et al.
Publicado: (2014)

Survival analysis with correlated endpoints: joint frailty-copula models
por: Emura, Takeshi, et al.
Publicado: (2019)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies
por: Messori, Andrea, et al.
Publicado: (2021)

A Likelihood Approach to Estimate the Number of Co-Infections
por: Schneider, Kristan A., et al.
Publicado: (2014)

Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint
por: Brückner, Matthias, et al.
Publicado: (2017)

Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
por: Shinno, Yuki, et al.
Publicado: (2018)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p0ck0pqtehuojgse938tvfge38